^
4ms
A Study of TAK-102 in Adult With Previously-Treated Solid Tumors (clinicaltrials.gov)
P1, N=11, Active, not recruiting, Takeda | Trial completion date: Dec 2026 --> Jul 2026 | Trial primary completion date: Dec 2026 --> Jul 2026
Trial completion date • Trial primary completion date
|
GPC3 (Glypican 3)
|
NIB102
11ms
A Study of TAK-102 in Adult With Previously-Treated Solid Tumors (clinicaltrials.gov)
P1, N=11, Active, not recruiting, Takeda | Recruiting --> Active, not recruiting | N=18 --> 11
Enrollment closed • Enrollment change
|
GPC3 (Glypican 3)
|
GPC3 expression
|
NIB102
over1year
Clinical • P1 data • Metastases
|
GPC3 (Glypican 3)
|
NIB102
over1year
A Study of TAK-102 in Adult With Previously-Treated Solid Tumors (clinicaltrials.gov)
P1, N=18, Recruiting, Takeda | Trial completion date: Jul 2023 --> Dec 2026 | Trial primary completion date: Jul 2023 --> Dec 2026
Trial completion date • Trial primary completion date
|
GPC3 (Glypican 3)
|
GPC3 expression
|
NIB102
2years
Interim results of a first-in-human Phase 1 dose-escalation trial of TAK-102, a glypican-3 targeted armored chimeric antigen receptor T-cell immunotherapy in patients with advanced solid tumors (SITC 2022)
TAK-102 is administered via a single infusion on 3 dose cohorts after lymphodepleting chemotherapy (fludarabine and cyclophosphamide): Cohort 1 (starting cohort), 1x10 7 CAR+ cells/body; Cohort 2, 1x10 8 CAR+ cells/body; Cohort 3, 1x10 9 CAR+ cells/body. Preliminary data show an encouraging safety profile and CK/PD results. The dose-escalation study is ongoing ( NCT04405778 ).
Clinical • P1 data • CAR T-Cell Therapy • IO biomarker
|
IFNG (Interferon, gamma) • AFP (Alpha-fetoprotein) • CD69 (CD69 Molecule) • GPC3 (Glypican 3) • IL10 (Interleukin 10) • CCL19 (C-C Motif Chemokine Ligand 19) • GZMB (Granzyme B) • IL7 (Interleukin 7) • GPI (Glucose-6-Phosphate Isomerase)
|
GPC3 expression • GPC3 positive
|
cyclophosphamide • fludarabine IV • NIB102
3years
A Study of TAK-102 in Adult With Previously-Treated Solid Tumors (clinicaltrials.gov)
P1, N=18, Recruiting, Takeda | Trial completion date: Nov 2022 --> Jul 2023 | Trial primary completion date: Nov 2022 --> Jul 2023
Clinical • Trial completion date • Trial primary completion date
|
GPC3 (Glypican 3)
|
GPC3 expression
|
NIB102
4years
A Study of TAK-102 in Adult Patients With GPC3-Expressing Previously Treated Solid Tumors (clinicaltrials.gov)
P1; N=18; Recruiting; Sponsor: Takeda; Not yet recruiting --> Recruiting
Enrollment open • Clinical
|
GPC3 (Glypican 3)
|
GPC3 expression
|
NIB102